Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 6/20 | 0.76 |
| ▸ | CHRNA4 | P43681 | 6/20 | 0.76 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.51 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.51 |
| ▸ | CHRNG | P07510 | 1/20 | 0.51 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.51 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.51 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.51 |
| ▸ | CHRND | Q07001 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL161236 | 0.96 | CHRNB2 (0.76) | CHRNB2CHRNA4CHRNA7CHRNA1CHRNG | |
| SCHEMBL29959593 | 0.96 | CHRNB2 (0.76) | CHRNB2CHRNA4CHRNA7CHRNA1CHRNG | |
| SCHEMBL30241910 | 0.94 | CHRNB2 (0.73) | CHRNB2CHRNA4CHRNA7CHRNA1CHRNG | |
| SCHEMBL1462348 | 0.94 | CHRNB2 (0.73) | CHRNB2CHRNA4CHRNA7CHRNA1CHRNG | |
| SCHEMBL30241909 | 0.94 | CHRNB2 (0.73) | CHRNB2CHRNA4CHRNA7CHRNA1CHRNG | |
| SCHEMBL5655570 | 0.88 | CHRNB2 (0.61) | CHRNB2CHRNA4 | |
| SCHEMBL5655866 | 0.87 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNA7CHRNA1CHRNG | |
| SCHEMBL23432733 | 0.84 | CHRNB2 (0.61) | CHRNB2CHRNA4CHRNA7CHRNB4CHRNA3 | |
| SCHEMBL3061045 | 0.84 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNA7CHRNA1CHRNG | |
| SCHEMBL6352765 | 0.84 | CHRNB2 (0.61) | CHRNB2CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025083630-A1 | HETEROAROMATIC COMPOUNDS AS MUSCARINIC M4 RECEPTOR POSITIVE ALLOSTERIC MODULATORS (M4 PAMS) | SUVEN LIFE SCIENCES LIMITED (IN) | 2025-04-24 | — | — | WO | claimed |
| CN-104684906-B | Nampt inhibitor | 艾伯维公司 | 2017-06-09 | — | — | CN | claimed |
| WO-2025134078-A1 | ORGANIC COMPOUNDS AS MUSCARINIC M4 RECEPTOR POSITIVE ALLOSTERIC MODULATORS (M4 PAMS) | SUVEN LIFE SCIENCES LIMITED (IN) | 2025-06-26 | — | — | WO | disclosed |
| WO-2025083630-A1 | HETEROAROMATIC COMPOUNDS AS MUSCARINIC M4 RECEPTOR POSITIVE ALLOSTERIC MODULATORS (M4 PAMS) | SUVEN LIFE SCIENCES LIMITED (IN) | 2025-04-24 | — | — | WO | disclosed |
| US-20220153732-A1 | PROTEIN SECRETION INHIBITORS | ENODIA THERAPEUTICS SAS (FR) | 2022-05-19 | — | — | US | disclosed |
| CN-109641898-B | 5, 7-dihydro-pyrrolo-pyridine derivatives for the treatment of neurological and neurodegenerative diseases | 辉瑞公司 | 2022-04-08 | — | — | CN | disclosed |
| CN-109641898-A | For treat nerve and neurodegenerative disease 5,7- dihydro-pyrrole simultaneously-pyridine derivate | 辉瑞公司 | 2019-04-16 | — | — | CN | disclosed |
| US-9758511-B2 | NAMPT inhibitors | ABBVIE INC. (US) | 2017-09-12 | — | — | US | disclosed |
| CN-104684906-B | Nampt inhibitor | 艾伯维公司 | 2017-06-09 | — | — | CN | disclosed |
| EP-2611788-B1 | NICOTINE COMPOUNDS AND ANALOGS THEREOF, SYNTHETIC METHODS OF MAKING COMPOUNDS, AND METHODS OF USE | UNIV FLORIDA (US) | 2017-04-12 | — | — | EP | disclosed |
| US-20170065575-A1 | NAMPT INHIBITORS | ABBVIE INC (US) | 2017-03-09 | — | — | US | disclosed |
| US-20150141398-A1 | NAMPT INHIBITORS | ABBVIE INC. | 2015-05-21 | — | — | US | disclosed |
| EP-2852585-A1 | NAMPT INHIBITORS | AbbVie Inc. (US) | 2015-04-01 | — | — | EP | disclosed |
| US-8975398-B2 | NAMPT inhibitors | ABBVIE INC. (US) | 2015-03-10 | — | — | US | disclosed |
| US-20140336168-A1 | NAMPT INHIBITORS | ABBVIE INC. | 2014-11-13 | — | — | US | disclosed |
| WO-2013170113-A1 | NAMPT INHIBITORS | ABBVIE INC. (US) | 2013-11-14 | — | — | WO | disclosed |
| US-20130303509-A1 | NAMPT INHIBITORS | ABBVIE INC. (US) | 2013-11-14 | — | — | US | disclosed |
| US-20130303510-A1 | NAMPT INHIBITORS | ABBVIE INC. (US) | 2013-11-14 | — | — | US | disclosed |
| US-4163856-A | Azetidine compounds and process for production | PHILIP MORRIS INCORPORATED (US) | 1979-08-07 | — | — | US | disclosed |
| US-4163856-A | Azetidine compounds and process for production | PHILIP MORRIS INCORPORATED (US) | 1979-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150141398-A1 | NAMPT INHIBITORS | NAMPT, NNMT, NAPRT | CHRNB2 1991/4885CHRNA4 2792/4885CHRNA7 2108/4885 |
| US-20170065575-A1 | NAMPT INHIBITORS | NAMPT, NNMT, NAPRT | CHRNB2 1991/4885CHRNA4 2792/4885CHRNA7 2108/4885 |
| US-20140336168-A1 | NAMPT INHIBITORS | NAMPT, NNMT, NAPRT | CHRNB2 1991/4885CHRNA4 2792/4885CHRNA7 2108/4885 |
| US-20220153732-A1 | PROTEIN SECRETION INHIBITORS | SEC61B, SEC61A1, SEC61G | CHRNB2 4568/4885CHRNA4 4847/4885CHRNA7 4744/4885 |
| US-20130303510-A1 | NAMPT INHIBITORS | NAMPT, NNMT, NAPRT | CHRNB2 1991/4885CHRNA4 2792/4885CHRNA7 2108/4885 |
| US-20130303509-A1 | NAMPT INHIBITORS | NAMPT, NNMT, NAPRT | CHRNB2 1991/4885CHRNA4 2792/4885CHRNA7 2108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.